

1 **Real world performance of inactivated SARS-CoV-2 vaccine (CoronaVac) against**
2 **infection, hospitalization and death due to COVID-19 in adult population in Indonesia**

3
4 Anton Suryatma^{1*}, Raras Anasi², Miko Hananto², Asep Hermawan¹, Ririn Ramadhany³, Irene
5 Lorinda Indalao³, Agustiningsih Agustiningsih¹, Ely Hujjatul Fikriyah², Kristina Lumban
6 Tobing¹, Teti Tejayanti², Rustika Rustika¹, Pandji Wibawa Dhewantara^{1*}

7
8 ¹ National Agency for Research and Innovation, Jl. M.H. Thamrin No. 8, Jakarta 10340,
9 Indonesia

10 ² Center for Policy on Global Health and Health Technology, Institute of Health Policy
11 Development, Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560,
12 Indonesia

13 ³ Center for Policy on Health System and Resources, Institute of Health Policy Development,
14 Ministry of Health of Indonesia, Jl. Percetakan Negara No. 29, Jakarta 10560, Indonesia

15
16 *Authors contributed equally

17
18 Correspondence: Anton Suryatma, MD, MPH., National Agency for Research and Innovation,
19 Jl. M.H. Thamrin No. 8, Jakarta 10340, Indonesia. Email: drantonsuryatma@gmail.com

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Abstract**

44 **Background:** Inactivated SARS-CoV-2 vaccine has been included in the national COVID-19
45 vaccination program in Indonesia since January 2021. The study aims to assess the impacts of
46 inactivated COVID-19 vaccine on infection, hospitalization, and death among adult population
47 aged ≥ 18 years in Bali, Indonesia.

48 **Methods:** Test-negative, case control study was conducted by linking SARS-CoV-2 laboratory
49 records, vaccination, and health administrative data for the period of January 13 to June 30,
50 2021. Case-subjects were defined as individuals who had a positive RT-PCR test for SARS-
51 CoV-2 during the period; they were matched with controls (tested negative) (1:1) based on age,
52 sex, district of residence, and week of testing. We estimated the odds of vaccination in PCR
53 confirmed, hospitalization and death due to COVID-19, accounting for the presence of
54 comorbidities and prior infection. Vaccine effectiveness was estimated as $(1 - \text{odds ratio}) \times$
55 100% .

56 **Results:**

57 Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021. Of
58 these, 14,168 subjects were eligible for inclusion in the study. Total 5518 matched case-control
59 pairs were analyzed. Adjusted vaccine effectiveness (VE) against laboratory-confirmed SARS-
60 CoV-2 infection was 14.5% (95% confidence interval -11 to 34.2) at 0-13 days after the first
61 dose; 66.7% (95% CI: 58.1- 73.5) at ≥ 14 days after the second dose. The adjusted effectiveness
62 against hospitalization and COVID-19-associated death was 71.1% (95% CI: 62.9-77.6) and
63 87.4% (95% CI: 65.1-95.4%) at ≥ 14 days after receiving the second dose, respectively.

64 **Conclusions:** Two-dose of inactivated CoronaVac vaccine showed high effectiveness against
65 laboratory confirmed COVID-19 infection, hospitalization, and death associated with COVID-
66 19 among adults aged ≥ 18 years.

67 **Keywords:** inactivated vaccine, COVID-19, effectiveness, test-negative, Indonesia

68 **Introduction**

69 Indonesia rolled-out the first phase of mass vaccination program on January 13th, 2021, using
70 the inactivated SARS-CoV-2 vaccine, CoronaVac, manufactured by Sinovac Life Sciences,
71 Beijing, China. In the first phase, mass COVID-19 vaccination was targeting healthcare
72 workers and general population including adults and elderly. A phase 1 and 2 clinical trial in
73 China indicated that CoronaVac was tolerable, with acceptable safety and immunogenicity, and
74 therefore supported the conduct of a phase 3 clinical trial in three countries including Indonesia
75 [1]. The efficacy of CoronaVac varied among the countries, ranging from 50.7% to 84% against
76 SARS-CoV-2 infection [2-4]. In Indonesia, two doses of CoronaVac vaccine had an efficacy
77 of 65.3% against COVID-19 illness after 14 days of injection; this supported the approval of
78 emergency use authorization (EUA) by the Indonesia National Agency of Drug and Food
79 Control (NADFC) [2, 5].

80 Evidence regarding the real-world effectiveness of inactivated CoronaVac vaccine against
81 SARS-CoV-2 infection, hospitalization, and death related with COVID-19 have been reported
82 in number of countries such as Chile, Turkey, and Brazil [6, 7]. These studies suggest that the
83 effectiveness of CoronaVac was varied from region to region. Therefore, since the performance
84 in the population found to be different from that reported efficacy under controlled trial
85 circumstances, post-licensure vaccine effectiveness evaluation at the population level is crucial
86 [8]. In Indonesia, study on evaluating CoronaVac vaccine performance in preventing COVID-
87 19 infection and severe outcomes is still limited especially in adults aged 18 years and above.
88 The objective of this study was to estimate vaccine effectiveness (VE) of inactivated
89 CoronaVac vaccine against COVID-19 infection, hospitalization, and COVID-19-related death
90 among adult aged ≥ 18 years in Bali.

91

92

93 **Materials and methods**

94 *Setting and design*

95 Bali is a one of the popular tropical islands in Indonesia, with a total land area of 5780 km²
96 and population of more than 4.3 million [9]. Mass COVID-19 vaccination using inactivated
97 SARS-CoV-2 (CoronaVac) was initiated by the Ministry of Health of Indonesia on January
98 13, 2021, across Indonesia, including in Bali. As of July 31, 2021, COVID-19 vaccines have
99 been given to 2.8 million (41.9%) of the targeted Balinese population. About 2.2 million
100 people aged ≥ 18 years had received at least one dose of COVID-19 vaccines (Supplementary
101 Figure S1); 1.2 million (43.1%) had received at least one dose of inactivated CoronaVac
102 vaccine [10]. The observation was conducted during January 13 to June 30, 2021. During
103 the study period, the incidence of COVID-19 was increased during January-February and
104 followed with a declining trend from March to June 2021. There was a sharp increase in
105 incidence in July due to B.1.617.2 (Delta) variants (Figure 2, Supplementary Figure S2).
106 We conducted a record-based retrospective, test-negative, matched case control (1:1) study
107 to evaluate the effectiveness of inactivated CoronaVac vaccine in preventing laboratory
108 confirmed SARS-CoV-2 infection, among adults (aged ≥ 18 years) during January to June
109 2021. This test negative design was chosen due to several reasons. First, accessibility to
110 individual data who were laboratory-tested for SARS-CoV-2 was feasible through the
111 national surveillance system; second, it was cost-effective and allowed for faster results; and
112 lastly, the design could better control for potential biases, including healthcare seeking
113 behavior and access to COVID-19 testing [11].

114

115 *Data sources*

116 We linked individual health electronic databases including SARS-CoV-2 reverse-transcription
117 polymerase chain reaction (RT-PCR) test results from the national laboratory testing database

118 (New All Record), COVID-19 vaccination registry, and hospitalization claims, managed by the
119 Ministry of Health of Indonesia, using unique national citizen identification number. Data with
120 foreign identification number and driving license number were excluded. We also checked the
121 consistency in identification number, name, date of birth and sex between these databases.
122 Confirmatory SARS-CoV-2 PCR test was performed on naso and/or oropharyngeal swab
123 specimens in COVID-19 reference laboratories.[12]

124

125 *Selection of cases and matched controls*

126 Cases were adults aged ≥ 18 years identified as those who had at least one COVID-19-like
127 symptom (fever with body temperature documented at $\geq 38^{\circ}\text{C}$, chills, cough, shortness of
128 breath, fatigue or malaise, sore throat, headache, runny nose, congestion, muscle aches, nausea
129 or vomiting, diarrhea, abdominal pain, altered sense of smell or taste) and were tested RT-PCR
130 positive for SARS-CoV-2, between January 13 to June 30, 2021; were not confirmed as positive
131 for SARS-CoV-2 in the last 90 days before the index date; and those who did not receive any
132 COVID-19 vaccines other than CoronaVac before sample collection. Controls were defined as
133 those who had negative RT-PCR test results during the same period, irrespective for symptoms;
134 and who did not receive any COVID-19 vaccines other than CoronaVac before sample
135 collection. Cases and control were matched based on age, sex, district of residence and week of
136 sample collection/testing.

137

138 *Vaccination status*

139 Vaccination status of the subjects was determined by referring to linked individual vaccination
140 record and was determined based on their SARS-CoV-2 test date. Fully vaccinated cases and
141 controls were defined as having two doses of CoronaVac at least 14 days before the sample
142 collection date. Adults who received no single dose of CoronaVac vaccine were defined as

143 unvaccinated and all other adults who received one dose at least 14 days before sample
144 collection date were defined as partially vaccinated.

145

146 *Statistical analysis*

147 Unadjusted and adjusted odds of vaccination between test-positive and test-negative pairs were
148 estimated using conditional logistic regression. Odds ratios (ORs) and 95% confidence interval
149 (CI) of vaccination in cases and controls was compared. Adjusted ORs were estimated from
150 models including age (by year, as continuous) and presence of comorbidities and prior SARS-
151 CoV-2 infection. There was a considerable proportion of missing data for comorbidities (79%).
152 Multiple imputation was performed with considering for covariates (age, sex, residence) and
153 outcome. Vaccine effectiveness (VE) was calculated as $(1-OR) \times 100\%$ and 95% CIs for
154 vaccine effectiveness estimates as $100 \times (1 - \text{upper or lower bounds of 95\% CI for adjusted OR})$
155 [13].

156 The effectiveness of CoronaVac against secondary outcomes (hospitalization and death due to
157 COVID-19) were estimated using a multivariable logistic regression, accounting for covariates
158 such as age, sex, district of residence, imputed presence of comorbidities and week of sample
159 collection. Subgroup analyses were also performed to assess VE based on the age group.

160 Sensitivity analysis was conducted on an unmatched population using a multivariable logistic
161 regression model, adjusted for age, sex, district of residence, presence of comorbidities and
162 week of testing. Statistical significance was set at $p\text{-value} < 0.05$. All statistical analyses were
163 conducted using STATA software version 15.0 (Stata Cooperation, College Station, Texas,
164 USA).

165

166

167

168 **Results**

169 *Study population*

170 Total 109,050 RT-PCR test results were retrieved during the January 13 to June 30, 2021
171 (Figure 1). Of which, 14,168 subjects were eligible for inclusion in the study. Of these, 2886
172 (20.4%) were tested positive for SARS-CoV-2 and 11,282 (79.6%) tested negative for SARS-
173 CoV-2 infection. Of these, 5518 (39%) matched case-control pairs were eligible for analysis
174 after matching by age, sex, geography (district of residence), and week of testing.

175 The characteristics of the study population and matched case-control pairs were presented in
176 Table 1. The median age of the overall study sample (n=14,168) was 50 years (interquartile
177 range, 31-65 years); 50.8% were aged ≥ 50 years. Thirty percent (n=4259) resided in Denpasar
178 city. Thirty four percent (n=4863) had received full vaccination; 42.5% (n=6016) had not
179 received vaccine. Those who receiving positive RT-PCR test results were appeared much older,
180 males, had at least one comorbidity and unvaccinated.

181 Among the case subjects, about 40% of subjects having comorbidities. Based on vaccination
182 status, 16,4% (n=453) had received two doses of CoronaVac vaccine. Nineteen percent (n=535)
183 case subjects had received the first dose of CoronaVac vaccine and about two-third (n=1771)
184 were unvaccinated. While among participants in the control group, half of the participants
185 (n=1485/2759) were unvaccinated. Twenty four percent had received two doses of CoronaVac
186 vaccine.

187

188 *Vaccine effectiveness*

189 The unadjusted effectiveness of two doses of CoronaVac in preventing laboratory confirmed
190 SARS-CoV-2 at least 14 days after administration was 73% (95% CI: 67-78) (Table 2). After
191 adjusting for covariates, compared to unvaccinated adults, two dose of CoronaVac improved
192 protection against SARS-CoV-2 infection (VE: 66.7%; 95% CI: 58.1-73.5) at ≥ 14 days after

193 the second dose. Partial vaccination with CoronaVac was not significantly associated with a
194 reduced risk of laboratory-confirmed SARS-CoV-2 infection (VE: 14.5%; 95% CI: -11 to 34.2)
195 at 0-13 days after the first dose. The effectiveness of CoronaVac vaccine against COVID-19
196 infection was reduced with increasing age.

197 The adjusted VE in preventing COVID-19-related hospitalization and death was 71.1% (95%
198 CI: 62.9-77.6) and 87.4% (95% CI: 65.1-95.4), respectively, at 14 days after the second dose
199 (Table 3). Partial vaccination was less protective against COVID-19-related hospitalization and
200 death among people aged 18 and older. Vaccine effectiveness against hospitalization was higher
201 79.4% (95% CI: 70-85.9) in group of people aged ≥ 50 years relative to people aged 18-49 years
202 (65.8%; 95% CI: 49.1-77). Death due to COVID-19 was not significantly associated with full
203 vaccination in people aged 18-49 years (VE: 65.7%, 95% CI: -99.5 to 94.1). This result could
204 be happened due to an effect of small sample size and small number of events (mortality).
205 Among older population, vaccine effectiveness was 90.6% (95% CI: 61.5-97.7) in preventing
206 death due to COVID-19.

207 To address potential issues related to the small sample size and rare event or outcome, we
208 conducted a sensitivity analysis using unmatched population (n=14,168) (Supplementary Table
209 S1 - Table S3). Overall, after adjusting all covariates, the vaccine effectiveness was 66.7%
210 (95%CI: 61-71.5) in preventing laboratory confirmed SARS-CoV-2 infection at 14 days or
211 more after the second dose administration. The effectiveness was relatively higher in adults
212 aged 18-49 years (VE: 76.9; 95%CI: 77.3-86.6) compared to that older participants (VE: 69.4%,
213 95%CI: 60.8-76.2), at 14 days after the second dose.

214 The effectiveness against hospitalization and death related to COVID-19 was 77.7% (95%CI:
215 73.2-81.5) and 93.9% (95%CI: 85-97.6%), respectively, at 14 days after second dose. The
216 effectiveness against both hospitalization and death due to COVID-19 was higher in that

217 population aged 50 years or older (82.6% and 94.4%, respectively) compared to group of people
218 aged 18-49 years (71.8% and 88.1%, respectively).

219

220 **Discussion**

221 High proportion of inactivated vaccine of CoronaVac have been used in national COVID-19
222 vaccination program in Indonesia. So far, this is the first health record-based observational
223 study that provide real-world evidence on the effectiveness of COVID-19 vaccine against
224 laboratory-confirmed SARS-CoV-2 infection, hospitalization, and death in Indonesian
225 population. The study showed complete regimen of CoronaVac vaccine at least 14 days after
226 the second dose had an effectiveness of 66.7% (95% CI: 58.1-73.5) against COVID-19 infection
227 among Balinese adults aged ≥ 18 years. This finding is consistent with the results of phase III
228 trial [5]. Yet, the effectiveness against infection was reduced by age. The effectiveness against
229 infection was slightly lower in elderly aged 50 years and above (69.9%; 95% CI: 57.7-78.7)
230 compared to younger adults (18-49 years) (77%, 95% CI: 66.6-84.2). This could be associated
231 with the difference in immune response. It has been observed in older people that the antibody
232 titre was rapidly degraded, the immune response was delay and the peak of neutralizing
233 antibodies was relatively lower than younger populations [14]. These findings highlight the
234 necessity for elderly-specific immunization approaches (e.g., vaccine formulations and
235 administration).

236 Our real-world evidence on the effectiveness of CoronaVac against laboratory confirmed
237 SARS-CoV-2 infection was consistent with that randomized controlled trials of vaccine
238 efficacy in Indonesia (65.3%; 95%CI: 20-85.1) [2]. Yet, it was lower than that of vaccine
239 efficacy reported in Turkey (83.5%; 95% CI: 65.4-92.1) and higher than that efficacy reported
240 from Brazil (51%; 95%CI: 36-62) at 14 days after the second vaccination [3, 15]. Chilean cohort
241 VE study involving general population aged ≥ 16 years old also demonstrated the VE was 65.9%

242 (95% CI: 65.2%-66.6%) against COVID-19 infection. While a TND case control study in Brazil
243 demonstrated that two dose regimens of CoronaVac was effective in reducing risk of
244 symptomatic COVID-19 (46.8%; 95% CI: 38.7% to 53.8%) at ≥ 14 days after the second dose
245 among older population aged ≥ 70 years [7]. Another inactivated vaccine platform, BBV152 (a
246 whole-virion inactivated vaccine manufactured by Bharat Biotech, Covaxin) which is used in
247 India, has also been reported to be effective against COVID-19. A study reported that the
248 effectiveness of against symptomatic COVID-19 was 50% (95% CI: 33–62) [16]. Compared to
249 the effectiveness of CoronaVac vaccine, BBV152 effectiveness is slightly lower. The difference
250 in the amount of transmission and the circulating SARS-CoV-2 variant are likely to have an
251 impact on the results.

252 Our study showed that full vaccination of CoronaVac vaccine was also effective in preventing
253 hospitalization and COVID-19-associated death. We estimated that CoronaVac vaccine was
254 71.1% (95% CI: 62.9-77.6) for the prevention of hospitalization and 87.4% (95% CI: 65.1-95.4)
255 for the prevention of COVID-19-related death at least 14 days after the second dose. While
256 partial vaccination provided less protection against hospitalization and death due to COVID-
257 19. None has reported CoronaVac VE estimates against these two outcomes in Indonesia. Our
258 estimates, however, are dissimilar to that estimate reported elsewhere. A cohort study in Chile
259 among adults aged ≥ 16 years showed that CoronaVac vaccine was 87.5% (95% CI, 86.7-88.2)
260 effective against hospitalization and 86.3% (95% CI, 84.5-87.9) effective against COVID-19–
261 related death [6, 17]. While a TND study in Brazil among elderly aged 70 years or older,
262 CoronaVac was effective against COVID-19-related hospitalization (55.5%; 95% CI: 46.5-
263 62.9) and death (61.2%, 95% CI: 48.9-70.5) at ≥ 14 days after the second dose, respectively [7].
264 A study on another inactivated vaccine showed that the effectiveness of full vaccination of
265 Sinopharm BBIBP-CorV was 79.8% (95% CI: 78–81.4) in preventing hospital admission and
266 97.1% (83–99.9) in preventing death among Abu Dhabi residents aged 15 years and older [18];

267 which is slightly higher than our estimates on the effectiveness of CoronaVac. This discrepancy
268 might be due to several factors including variation in study population and design (e.g., targeted
269 age group, sample size) and difference in level of transmission or epidemiological setting (e.g.,
270 a TND study in Brazil was conducted when P.1 or Gamma variant was predominant).

271 Our adjusted effectiveness

272 The strengths of this study are that: i) we used comprehensive health administrative database
273 including individual laboratory test results, vaccination data and hospitalizations which include
274 information on date of sample collection, type of vaccine, date of vaccination, date of hospital
275 admission and underlying conditions; (ii) the subjects were chosen based on a standard
276 laboratory confirmation for SARS-CoV-2 results. Thus, biases due to misclassification from
277 infection or vaccination status were implausible. These findings are important to fill the gap in
278 our knowledge regarding the performance of inactivated CoronaVac vaccine in the real-world;
279 (iii) our analysis have sufficient of power (99.3%) as our matched case-control study involved
280 large number of samples (2759 cases) with known vaccine effectiveness of 65% against
281 symptomatic SARS-CoV-2 ≥ 14 days after the second dose.

282 However, our study has limitations. First, while we attempted to make a robust approach by
283 adjusting for number of potential confounding factors, including age, sex, geography, week of
284 testing (sample collection) and presence of comorbidities, there might be still unmeasured
285 confounding factors that biased the VE estimates (e.g., behavioral risk factors, type of variants).

286 Second, we did not have a detailed information on symptoms and date of onset in the record so
287 that we could not identified and specifically examine the effectiveness against symptomatic
288 cases. Third, as the data for date on onset were not available in the records, we used date of
289 sample collection instead. There might be false-negative results included in the study so that
290 this could affect our estimate. Lastly, this study was retrieved data from January to June 2021,
291 which was just before the peak of Delta variants (B.1.617.2) outbreaks. Hence, the VE estimates

292 presented here is likely reflected vaccine performance before Delta and Omicron becoming
293 predominant variant in the community. VE of CoronaVac against Delta and Omicron-related
294 infection and severity might be different. Studies elsewhere have reported the effects of Delta
295 variants on the COVID-19 vaccines performance [19, 20]. Further research is required to
296 evaluate the effectiveness of CoronaVac against the circulating VOCs.

297

298 **Conclusions**

299 The two-dose regimens of inactivated CoronaVac vaccine was effective in preventing COVID-
300 19 infection, hospitalizations for COVID-19 and COVID-19-related death in adults aged 18
301 years or older. Full vaccination was significantly reduced the risk of severe outcomes especially
302 among 50 years or older.

303

304 **Author contributions**

305 Study conceptualization: AS, PWD, RR (Ririn Ramadhany), MH. Methodology: AS, RR (Ririn
306 Ramadhany), MH, PWD. Formal analysis: AS, RA, EHF, PWD, MH. Project administration:
307 RA, RR (Rustika Rustika), KLT, TT. Data collection: AS, RA, EHF, AA, ILI, PWD.
308 Supervision: PWD, RR (Ririn Ramadhany). Validation: PWD, RR (Rustika Rustika), KLT, TT.
309 Funding: AS, TT, MH. Writing (original draft): AS, PWD. Writing (review and editing): all
310 authors. All authors have read and approved the manuscript.

311

312 **Ethic statement**

313 The protocol of the study was approved by the Health Research Ethics Committee, National
314 Institute of Health Research and Development, Ministry of Health, Indonesia (LB.
315 02.01/2/KE.533/2021). The study was considered exempt from informed consent. No human
316 health risks were identified.

317

318 **Conflict of interest**

319 The authors declare that they have no competing interests. None of us received shares or any
320 kind monetary compensation linked to the distribution of CoronaVac in Indonesia or have any
321 share or financial interests in Sinovac Life Sciences or parent companies.

322

323 **Data availability statement**

324 The datasets used and/or analyzed during the current study are protected by the Ministry of
325 Health of Indonesia and are unsuitable for public sharing. Interested parties can apply for the
326 data by contacting the data center of the Ministry of Health of Indonesia. All data generated or
327 analyzed during this study are included in this published article (and its Supplementary
328 information files). Aggregate data on vaccination and COVID-19 incidence are publicly
329 available at <https://vaksin.kemkes.go.id/#/vaccines>

330

331 **Funding**

332 This study was funded by the National Institute of Health Research and Development, Ministry
333 of Health, Indonesia. The funders had no role in study design, data collection and analysis,
334 decision to publish, or preparation of the manuscript. The views expressed in this publication
335 are those of the authors and not necessarily those of the Ministry of Health of Indonesia.

336

337 **Acknowledgment**

338 We would like to thank Dr. Anas Ma'ruf and team at the Center of Health Data and Information
339 of Ministry of Health Indonesia, and Mr. Made Darmawan and Mr. Akbar Antony Siregar at
340 the National COVID-19 Control and Economic Recovery Committee (KPC-PEN) for their
341 assistance and support in collating the data. We would also like to thank the Ketut Suarjaya and

342 I Wayan Widia at Bali Provincial Health Office for their support in the implementation of this
343 study and permission to access COVID-19 surveillance data.

344

345

346 **References**

- 347 1. Y. Zhang, G. Zeng, H. Pan, C. Li, Y. Hu, K. Chu, W. Han, Z. Chen, R. Tang, W. Yin, X.
348 Chen, Y. Hu, X. Liu, C. Jiang, J. Li, M. Yang, Y. Song, X. Wang, Q. Gao, and F. Zhu,
349 "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy
350 adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2
351 clinical trial," *Lancet Infect Dis*, vol. 21, no. 2, pp. 181-192, 2021.
- 352 2. Indonesia National Agency of Drug and Food Control, "Emergency Use Authorization -
353 CoronaVac," Indonesia National Agency of Drug and Food Control Jakarta, 2021.
- 354 3. M. D. Tanriover, H. L. Doğanay, M. Akova, H. R. Güner, A. Azap, S. Akhan, Ş. Köse, F.
355 Ş. Erdinç, E. H. Akalın, Ö. F. Tabak, H. Pullukçu, Ö. Batum, S. Şimşek Yavuz, Ö. Turhan,
356 M. T. Yıldırım, İ. Köksal, Y. Taşova, V. Korten, G. Yılmaz, M. K. Çelen, S. Altın, İ. Çelik,
357 Y. Bayındır, İ. Karaoğlan, A. Yılmaz, A. Özkul, H. Gür, S. Unal, and G. CoronaVac Study,
358 "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac):
359 interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey,"
360 *Lancet (London, England)*, vol. 398, no. 10296, pp. 213-222, 2021.
- 361 4. R. Palacios, E. G. Patiño, R. de Oliveira Piorelli, M. T. R. P. Conde, A. P. Batista, G. Zeng,
362 Q. Xin, E. G. Kallas, J. Flores, C. F. Ockenhouse, and C. Gast, "Double-Blind,
363 Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and
364 Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated)
365 Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study
366 protocol for a randomised controlled trial," *Trials*, vol. 21, no. 1, pp. 853-853, 2020.
- 367 5. E. Fadlyana, K. Rusmil, R. Tarigan, A. R. Rahmadi, S. Prodjosoeowojo, Y. Sofiatin, C. V.
368 Khrisna, R. M. Sari, L. Setyaningsih, F. Surachman, N. S. Bachtiar, H. Sukandar, I.
369 Megantara, C. Murad, K. N. A. Pangesti, V. Setiawaty, S. Sudigdoadi, Y. Hu, Q. Gao, and
370 C. B. Kartasasmita, "A phase III, observer-blind, randomized, placebo-controlled study of
371 the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy
372 adults aged 18-59 years: An interim analysis in Indonesia," *Vaccine*, vol. 39, no. 44, pp.
373 6520-6528, 2021.
- 374 6. Ministerio de Salud Gobierno de Chile, "Effectiveness of the inactivated CoronaVac
375 vaccine against SARS-CoV-2 in Chile - Preliminary report," Ministerio de Salud, Chile, 2021.
- 376 7. O. T. Ranzani, M. D. T. Hitchings, M. Dorion, T. L. D'Agostini, R. C. de Paula, O. F. P. de
377 Paula, E. F. M. Villela, M. S. S. Torres, S. B. de Oliveira, W. Schulz, M. Almiron, R. Said,

- 378 R. D. de Oliveira, P. Vieira da Silva, W. N. de Araújo, J. C. Gorinchteyn, J. R. Andrews,
379 D. A. T. Cummings, A. I. Ko, and J. Croda, "Effectiveness of the CoronaVac vaccine in
380 older adults during a gamma variant associated epidemic of covid-19 in Brazil: test
381 negative case-control study," *Bmj*, vol. 374, pp. n2015, 2021.
- 382 8. G. Hanquet, M. Valenciano, F. Simondon, and A. Moren, "Vaccine effects and impact of
383 vaccination programmes in post-licensure studies," *Vaccine*, vol. 31, no. 48, pp. 5634-42,
384 2013.
- 385 9. Provincial Bureau of Statistics of Bali, *Bali in Figure 2021*, Provincial Bureau of Statistics
386 of Bali, Denpasar, 2021.
- 387 10. Ministry of Health of Indonesia, "COVID-19 Vaccine Dashboard," Ministry of Health of
388 Indonesia, <https://vaksin.kemkes.go.id/#/vaccines>.
- 389 11. M. K. Patel, I. Bergeri, J. S. Bresee, B. J. Cowling, N. S. Crowcroft, K. Fahmy, S. Hirve,
390 G. Kang, M. A. Katz, C. F. Lanata, M. L'Azou Jackson, S. Joshi, M. Lipsitch, J. M. Mwenda,
391 F. Nogareda, W. A. Orenstein, J. R. Ortiz, R. Pebody, S. J. Schrag, P. G. Smith, P.
392 Srikantiah, L. Subissi, M. Valenciano, D. W. Vaughn, J. R. Verani, A. Wilder-Smith, and
393 D. R. Feikin, "Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary
394 of interim guidance of the World Health Organization," *Vaccine*, vol. 39, no. 30, pp. 4013-
395 4024, 2021.
- 396 12. Ministry of Health of Indonesia, *Guidelines on COVID-19 Prevention and Control, 5th*
397 *revision* Ministry of Health of Indonesia, Jakarta, 2020.
- 398 13. W. A. Orenstein, R. H. Bernier, T. J. Dondero, A. R. Hinman, J. S. Marks, K. J. Bart, and
399 B. Sirotkin, "Field evaluation of vaccine efficacy," *Bulletin of the World Health*
400 *Organization*, vol. 63, no. 6, pp. 1055-1068, 1985.
- 401 14. D. A. Collier, I. Ferreira, P. Kotagiri, R. P. Datir, E. Y. Lim, E. Touizer, B. Meng, A.
402 Abdullahi, A. Elmer, N. Kingston, B. Graves, E. Le Gresley, D. Caputo, L. Bergamaschi,
403 K. G. C. Smith, J. R. Bradley, L. Ceron-Gutierrez, P. Cortes-Acevedo, G. Barcenas-
404 Morales, M. A. Linterman, L. E. McCoy, C. Davis, E. Thomson, P. A. Lyons, E. McKinney,
405 R. Doffinger, M. Wills, and R. K. Gupta, "Age-related immune response heterogeneity to
406 SARS-CoV-2 vaccine BNT162b2," *Nature*, vol. 596, no. 7872, pp. 417-422, 2021.
- 407 15. World Health Organization, *Interim recommendations for use of the inactivated COVID-19*
408 *vaccine, CoronaVac, developed by Sinovac (Interim Guidance 24 May 2021)*, World
409 Health Organization, Geneva, 2021.
- 410 16. D. Desai, A. R. Khan, M. Soneja, A. Mittal, S. Naik, P. Kodan, A. Mandal, G. T. Maher, R.
411 Kumar, A. Agarwal, N. R. Gowda, V. H, P. Kumar, S. Pandey, R. M. Pandey, A. Kumar,
412 A. Ray, P. Jorwal, N. Nischal, A. Choudhary, M. Brijwal, K. Madan, R. Lodha, S. Sinha, L.
413 Dar, N. Wig, and R. Guleria, "Effectiveness of an inactivated virus-based SARS-CoV-2

- 414 vaccine, BBV152, in India: a test-negative, case-control study," *The Lancet Infectious*
415 *Diseases*, vol. 22, no. 3, pp. 349-356, 2022.
- 416 17. A. Jara, E. A. Undurraga, C. González, F. Paredes, T. Fontecilla, G. Jara, A. Pizarro, J.
417 Acevedo, K. Leo, F. Leon, C. Sans, P. Leighton, P. Suárez, H. García-Escorza, and R.
418 Araos, "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile," *New England*
419 *Journal of Medicine*, vol. 385, no. 10, pp. 875-884, 2021.
- 420 18. F. Ismail AlHosani, A. Eduardo Stanciole, B. Aden, A. Timoshkin, O. Najim, W. Abbas
421 Zaher, F. AlSayedsaleh AlDhaheeri, S. Al Mazrouie, T. A. Rizvi, and F. Mustafa, "Impact of
422 the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in
423 infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United
424 Arab Emirates (UAE)," *Vaccine*, pp. S0264-410X(22)00174-8, 2022.
- 425 19. J. Lopez Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe,
426 E. Tessier, N. Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M.
427 Edmunds, M. Zambon, K. E. Brown, S. Hopkins, M. Chand, and M. Ramsay,
428 "Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant," *The New*
429 *England journal of medicine*, vol. 385, no. 7, pp. 585-594, 2021.
- 430 20. X.-N. Li, Y. Huang, W. Wang, Q.-L. Jing, C.-H. Zhang, P.-Z. Qin, W.-J. Guan, L. Gan, Y.-
431 L. Li, W.-H. Liu, H. Dong, Y.-T. Miao, S.-J. Fan, Z.-B. Zhang, D.-M. Zhang, and N.-S.
432 Zhong, "Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant
433 infection in Guangzhou: a test-negative case-control real-world study," *Emerging*
434 *microbes & infections*, vol. 10, no. 1, pp. 1751-1759, 2021.
- 435

1 **Table and Figure Legends**

2

3 **Table 1.** Characteristics of the adults aged ≥ 18 years eligible in the study and case-control
4 pairs included in the analysis

5

6 **Table 2.** CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2
7 infection in adults aged ≥ 18 years in Bali, Indonesia, all age and stratified by age group

8

9 **Table 3.** CoronaVac vaccine effectiveness in preventing hospitalization and COVID-19-
10 related death in adults aged ≥ 18 years in Bali, Indonesia, all ages and stratified by age group

11

12

13 **Figure 1.** Flowchart for case and control selection

14

15 **Figure 2.** Trends in COVID-19 incidence in Bali over the period of study (Data source:
16 Ministry of Health of Indonesia).





Figure 1. Flowchart for case and control selection

17
18
19
20
21



22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Figure 2. Trends in COVID-19 incidence in Bali over the period of study (Data source: Ministry of Health of Indonesia).

54 **Table 1.** Characteristics of the adults aged ≥ 18 years eligible in the study and case-control
 55 pairs included in the analysis
 56

Characteristics	Total	Eligible study population		Matched pairs	
		Positive SARS-CoV-2 (n=2886)	Negative SARS-CoV-2 (n=11,282)	Cases (n=2759)	Controls (n=2759)
Age, years, median (IQR)	50 (31-65)	61 (45-69)	46 (30-64)	61 (45-69)	60 (41-70)
Age group, n (%)					
18-49 y	6969 (49.2)	853 (29.6)	6116 (54.2)	847 (30.7)	847 (30.7)
≥ 50 y	7199 (50.8)	2033 (70.4)	5166 (45.8)	1912 (69.3)	1912 (69.3)
Sex					
Male	7676 (54.2)	1730 (59.9)	5946 (52.7)	1648 (59.7)	1648 (59.7)
Female	6492 (45.8)	1156 (40.1)	5336 (47.3)	1111 (40.3)	1111 (40.3)
District of residence, n (%)					
Jembrana	564 (4)	87 (3)	477 (4.2)	75 (2.7)	75 (2.7)
Tabanan	1500 (10.6)	233 (8.1)	1267 (11.2)	233 (8.5)	233 (8.5)
Badung	2031 (14.3)	474 (16.4)	1557 (13.8)	465 (16.7)	456 (16.7)
Gianyar	1573 (11.1)	408 (14.1)	1165 (10.3)	363 (13.2)	363 (13.2)
Klungkung	554 (3.9)	79 (2.7)	475 (4.2)	73 (2.7)	73 (2.7)
Bangli	803 (5.7)	222 (7.7)	581 (5.2)	202 (7.3)	202 (7.3)
Karangasem	916 (6.5)	144 (5)	772 (6.8)	138 (5)	138 (5)
Buleleng	1968 (13.9)	353 (12.2)	1615 (14.3)	343 (12.4)	343 (12.4)
Denpasar	4259 (30.1)	886 (30.7)	3373 (29.9)	867 (31.4)	867 (31.4)
Reported No. of comorbidities, n (%)					
No	12,158 (85.8)	1698 (58.8)	10,460 (92.7)	1636 (59.3)	2473 (89.6)
Yes	2010 (14.2)	1188 (41.2)	822 (7.3)	1123 (40.7)	286 (10.4)
Vaccination status, n (%)					
Unvaccinated	6016 (42.5)	1867 (64.7)	4149 (36.8)	1771 (64.2)	1469 (53.3)
1st dose (0-13 days)	1001 (7.1)	222 (7.7)	779 (6.9)	216 (7.8)	193 (7)
1st dose (≥ 14 days)	1408 (9.9)	340 (11.8)	1068 (9.5)	319 (11.6)	272 (9.9)
2nd dose (0-13 days)	880 (6.2)	77 (2.7)	803 (7.1)	74 (2.7)	158 (5.7)
2nd dose (≥ 14 days)	4863 (34.3)	380 (13.2)	4483 (39.7)	379 (13.7)	667 (24.2)

57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74

75
76
77
78

Table 2. CoronaVac vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection in adults aged ≥ 18 years in Bali, Indonesia, all age and stratified by age group

	Cases (SARS-CoV-2 RT-PCR- positive)	Controls (SARS-CoV-2 RT-PCR- negative)	Unadjusted OR (95% CI)	Unadjusted p-value	Adjusted OR* (95% CI)	Adjusted p-value	Adjusted VE (95% CI)
Unvaccinated	1771 (64.2)	1469 (53.3)	Ref		Ref		
0-13 days after 1 st dose	216 (7.8)	193 (7)	0.77 (0.61-0.98)	0.03	0.85 (0.66-1.11)	0.239	14.5 (-11 – 34.2)
≥ 14 days after 1 st dose	319 (11.6)	272 (9.9)	0.76 (0.62-0.93)	0.007	0.89 (0.71-1.12)	0.332	10.5 (-12 – 28.6)
0-13 days after 2 nd dose	74 (2.7)	158 (5.7)	0.33 (0.24-0.45)	<0.0001	0.37 (0.26-0.52)	<0.0001	63.1 (48.5-73.6)
≥ 14 days after 2 nd dose	379 (13.7)	667 (24.2)	0.27 (0.22-0.33)	<0.0001	0.33 (0.26-0.42)	<0.0001	66.7 (58.1-73.5)
Age group: 18-49 years							
Unvaccinated	247 (29.2)	95 (11.2)	Ref		Ref		
0-13 days after 1 st dose	133 (15.7)	122 (14.4)	0.43 (0.29-0.62)	<0.0001	0.52 (0.35-0.77)	<0.0001	48.3 (22.6-65.5)
≥ 14 days after 1 st dose	144 (17)	131 (15.5)	0.34 (0.23-0.51)	<0.0001	0.45 (0.30-0.68)	<0.0001	55.1 (32-70.4)
0-13 days after 2 nd dose	39 (4.6)	79 (9.3)	0.20 (0.12-0.32)	<0.0001	0.22 (0.13-0.36)	<0.0001	78.2 (63.6-87)
≥ 14 days after 2 nd dose	284 (33.5)	420 (49.6)	0.18 (0.12-0.25)	<0.0001	0.23 (0.16-0.33)	<0.0001	77 (66.6-84.2)
Age group: ≥ 50 years							
Unvaccinated	1524 (79.7)	1374 (71.9)	Ref		Ref		
0-13 days after 1 st dose	83 (4.3)	71 (3.7)	1.05 (0.75-1.47)	0.775	1.11 (0.74-1.64)	0.617	-10.6 (-64.3– 25.5)
≥ 14 days after 1 st dose	175 (9.2)	141 (7.4)	1.02 (0.80-1.30)	0.874	1.13 (0.85-1.51)	0.396	-13.2 (-50.6 – 14.9)
0-13 days after 2 nd dose	35 (1.8)	79 (4.1)	0.38 (0.25-0.58)	<0.0001	0.42 (0.26-0.68)	<0.0001	58.1 (32.4-74)
≥ 14 days after 2 nd dose	95 (4.9)	247 (12.9)	0.26 (0.19-0.35)	<0.0001	0.30 (0.21-0.42)	<0.0001	69.9 (57.7-78.7)

79
80
81
82
83
84
85
86

Abbreviations: OR, odds ratio; VE, vaccine effectiveness

*Adjusted for age (as continuous), presence of comorbidities and prior SARS-CoV-2 infection

† Vaccine effectiveness is calculated as (1- odds ratio) x 100%

87 **Table 3.** CoronaVac vaccine effectiveness in preventing hospitalization and COVID-19-related death in adults aged ≥ 18 years in Bali,
 88 Indonesia, all ages and stratified by age group
 89

	Hospitalization				Death due to COVID-19			
	n/N	Adjusted OR (95% CI)	Adjusted p-value	VE* % (95%CI)	n/N	Adjusted OR (95% CI)	Adjusted p-value	VE* % (95%CI)
Unvaccinated	1932/3240	Ref			450/3240	Ref		
0-13 days after 1 st dose	124/409	0.72 (0.54-0.95)	0.019	28.3 (5.3-45.7)	10/409	0.46 (0.24-0.90)	0.023	53.9 (10-76.3)
≥ 14 days after 1 st dose	218/591	0.66 (0.52-0.84)	0.001	34.1 (16.4-48.1)	15/591	0.41 (0.24-0.72)	0.002	58.6 (28.3-76.1)
0-13 days after 2 nd dose	50/232	0.39 (0.26-0.57)	<0.0001	61.2 (42.6-73.7)	3/232	0.24 (0.07-0.77)	0.017	76 (22.9-92.5)
≥ 14 days after 2 nd dose	166/1048	0.29 (0.22-0.37)	<0.0001	71.1 (62.9-77.6)	4/1046	0.13 (0.05-0.35)	<0.0001	87.4 (65.1-95.4)
Age group: 18-49 years								
Unvaccinated	123/342			Ref	11/342			Ref
0-13 days after 1 st dose	53/255	0.66 (0.43-1.02)	0.062	33.7 (-2.1-56.9)	0/255	1	-	NA**
≥ 14 days after 1 st dose	65/275	0.67 (0.44-1.02)	0.064	32.6 (-2.3-55.6)	1/275	0.22 (0.02-2.05)	0.184	77.9 (-105.4-97.6)
0-13 days after 2 nd dose	16/118	0.33 (0.17-0.65)	0.001	66.9 (35-83.2)	1/118	0.30 (0.03-2.97)	0.303	70 (-196.5-97)
≥ 14 days after 2 nd dose	99/704	0.35 (0.23-0.52)	<0.0001	65.1 (48-76.5)	2/704	0.45 (0.07-2.80)	0.390	55.3 (-180.2-92.9)
Age group: ≥ 50 years								
Unvaccinated	1809/2898			Ref	439/2898			Ref
0-13 days after 1 st dose	71/154	0.86 (0.58-1.27)	0.446	14.1 (-27.1-42)	10/154	0.65 (0.33-1.28)	0.213	34.9 (-28-66.9)
≥ 14 days after 1 st dose	153/316	0.67 (0.50-0.90)	0.009	32.9 (9.5-50.2)	14/316	0.45 (0.25-0.79)	0.005	55.2 (21.1-74.6)
0-13 days after 2 nd dose	34/114	0.44 (0.27-0.72)	0.001	55.9 (28-72.9)	2/114	0.20 (0.05-0.82)	0.025	80.2 (18.1-95.2)
≥ 14 days after 2 nd dose	67/342	0.21 (0.15-0.30)	<0.0001	79 (69.7-85.5)	2/342	0.09 (0.02-0.37)	0.001	90.9 (62.6-97.8)

90 Abbreviations: OR, odds ratio; VE, vaccine effectiveness; CI, confidence interval

91 *Adjusted for age (as continuous), sex, presence of comorbidities and prior SARS-CoV-2 infection, week of testing, district of residence. OR is estimated using
 92 multivariable regression model.

93 **The CI could not be estimated owing to zero/few events in the group.

94

95

96

97